Bionano Genomics Announces Six User Presentations of OGM Results in Cancer Genomics Research at the Spanish Society of Hematology (SEHH) 2022
Bionano Genomics (BNGO) announced its participation in the Spanish Society of Hematology (SEHH) 2022 Conference, taking place from October 6-8 in Barcelona. The company featured six scientific presentations showcasing the applications of its optical genome mapping (OGM) technology in hematologic malignancies like leukemias and lymphomas. These independent studies emphasize OGM's utility in cancer genomics and cytogenetic diagnosis, potentially positioning it as a vital tool for future cancer research.
- Six scientific presentations at SEHH 2022 highlight the application of OGM in cancer genomics.
- Demonstrates OGM's potential utility in diagnosing hematologic malignancies.
- Forward-looking statements indicate potential risks associated with OGM adoption and research outcomes.
SAN DIEGO, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its participation at the Spanish Society of Hematology (SEHH) 2022 Conference, with six scientific presentations from independent researchers covering a wide variety of the cancer genomics landscape, highlighting the application of optical genome mapping (OGM) for hematologic malignancies and cancer research.
SEHH 2022 is a three-day conference dedicated to basic, preclinical and translational cancer research. SEHH sessions will take place October 6-8, 2022 in Barcelona, Spain. Six separate scientific presentations delivered by faculty and clinicians from Spanish hematology institutes, cancer centers and hospitals will illustrate the application of Bionano’s OGM solutions in blood cancer research areas including leukemias, lymphomas and myelofibrosis.
Scientific presentations on OGM include:
| Presentation | Title | Author | Presented |
| Monoclonal Gammopathies CO-001 | Optical Genome Mapping: Validation and Utility in Cytogenetic Diagnosis of Multiple Myeloma | Cisneros A. | October 6, 2022 15:30-16:30 CEST Room 6 |
| Chronic Myeloproliferative Syndromes CO-124 | Cytogenetic Diagnosis by Optical Mapping Genomics in Patients with Myelofibrosis | Díaz-González, A. | October 7, 2022 15:45-16:45 CEST VIP Room |
| Monoclonal Gammopathies CO-010 | Prognostic Impact of the Cytogenetic Study by FISH Against Optical Genome Mapping in Patients with Newly Diagnosed Multiple Myeloma | De Jaureguizar, A. | October 8, 2022 15:30-17:00 CEST Room 6 |
| Leukemias CO-050 | Application of Genomic Optical Mapping in Patients with Acute Lymphoblastic Leukemia B for the Detection of Chromosomal Structural Variants | Avetisyan, G. | October 8, 2022 15:30-17:00 CEST Room 8 |
| Lymphomas CO-101 | Utility of the Optical Genome Mapping Technique in the Study of Splenic Marginal Zone Lymphoma | Salido Galeote, M. | October 8, 2022 15:30-17:00 CEST Room 1 PB |
| Hematologic Biology CO-155 | Clinical Utility of Optical Genome Mapping for the Cytogenetic Study in Acute Leukemias: Study Pilot in a Center | Puiggros, A. | October 8, 2022 15:30-17:00 CEST Room 1 |
More details on the conference can be found here.
“We believe the information covered in these SEHH presentations demonstrates the potential of OGM becoming an essential tool in the arsenal of cancer researchers across Spain,” commented Erik Holmlin, president and chief executive officer of Bionano. “These presentations point to the continued expansion of OGM into clinical research applications for hematological malignancies and we are excited to see how much more of an impact OGM may make in the future.”
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. Through its BioDiscovery business, the Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view. For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com.
Forward-Looking Statements of Bionano Genomics
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “potential,” “may,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the utility of OGM in cancer and hematologic research. Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the impact of the COVID-19 pandemic on our business and the global economy; general market conditions; changes in the competitive landscape and the introduction of competitive technologies or improvements to existing technologies; failure of the adoption of OGM as a tool for cancer or hematologic research; future study results contradicting the results reported in the presentations given and posters made available at the SEHH 2022 Conference; changes in our strategic and commercial plans; our ability to obtain sufficient financing to fund our strategic plans and commercialization efforts; the ability of medical and research institutions to obtain funding to support adoption or continued use of our technologies; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2021 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com
FAQ
What is Bionano Genomics presenting at SEHH 2022?
When is the SEHH 2022 Conference?
What are the key topics covered in Bionano's presentations?
What does the future hold for optical genome mapping according to Bionano Genomics?
How does Bionano's technology assist in cancer research?
